-
Mashup Score: 0Targeted Therapy Provides Greatest OS Benefit if Started Within 1 Month of NSCLC Diagnosis - Oncology Nurse Advisor - 2 day(s) ago
A new study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell lung cancer diagnosis can still improve overall survival, when compared to other first-line therapies.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Knowledge of Genomic Testing, Treatment Options Is Lacking Among Women With Breast Cancer - Oncology Nurse Advisor - 3 day(s) ago
Researchers sought to measure the knowledge and understanding of genetic and genomic testing and their influence on treatment decisions and options.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Disparities Persist in Use of Auto-HCT Among Patients With Multiple Myeloma - Oncology Nurse Advisor - 4 day(s) ago
Using a novel link between 3 California databases, researchers explored the barriers to autologous HCT for patients with multiple myeloma by race/ethnicity and socioeconomic status.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Comorbidity Patterns With Nasopharyngeal Carcinoma May Affect Outcomes in the Elderly - Oncology Nurse Advisor - 5 day(s) ago
Researchers sought to identify comorbidity patterns and their effect on outcomes for elderly patients with nasopharyngeal carcinoma.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Pathologic Complete Response May Predict DFS, OS in Soft Tissue Sarcoma - Oncology Nurse Advisor - 6 day(s) ago
Pathologic complete response is associated with improved long-term outcomes in patients with soft tissue sarcoma, a study suggests.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Liposomal Irinotecan Produces Similar PFS, OS as Topotecan in SCLC - Oncology Nurse Advisor - 7 day(s) ago
Liposomal irinotecan produced similar survival results as topotecan when used as second-line therapy in patients with SCLC.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Leukocyte Count in Robot vs Video Thoracic Surgery As Surgical Stress Indicator - Oncology Nurse Advisor - 8 day(s) ago
Researchers analyzed the surgical stress response and tissue trauma in patients with NSCLC after robot-assisted and video-assisted procedures using leukocyte count as a surrogate measure.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Web-Based Modules Set to Improve Caregiver Involvement in Cancer Care - Oncology Nurse Advisor - 9 day(s) ago
Researchers sought to develop and implement a web-based tool to enhance involvement, communication, and shared decision making among clinicians, patients with cancer, and their caregivers.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Diet Quality a Significant Factor in Risk of CVD for Breast Cancer Survivors - Oncology Nurse Advisor - 10 day(s) ago
Using a cohort from the Pathways Study, researchers sought to determine the influence of healthy eating habits on risk of heart disease among women treated for breast cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Nurse Insights for Managing CRS in Patients With RRMM Receiving Teclistamab - Oncology Nurse Advisor - 11 day(s) ago
Nurse insights from the MajesTEC-1 trial and a survey of nurses was used to identify management options for CRS in this patient population.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
Study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell #lungcancer diagnosis can still improve OS, when compared to other first-line therapies. From @ScienceDirect and @cancertheradvsr. https://t.co/AJJnq6MQ4O #NSCLC #LCSM